Heparin resistance (unresponsiveness to heparin) is characterized by the inability to reach acceptable activated clotting time values following a calculated dose of heparin. Up to 20% of the patients undergoing cardiothoracic surgery with cardiopulmonary bypass using unfractionated heparin (UFH) for anticoagulation experience heparin resistance. Although UFH has been the “gold standard” for anticoagulation, it is not without its limitations. It is contraindicated in patients with confirmed heparin-induced thrombocytopenia (HIT) and heparin or protamine allergy. The safety and efficacy of the use of the direct thrombin inhibitor bivalirudin for anticoagulation during cardiac surgery has been reported. However, there have been no reports on the treatment of heparin resistance with bivalirudin during CPB. In this review, we report the favorable outcome of our single-center experience with the alternative use of bivalirudin in the management of anticoagulation of heparin unresponsive patients undergoing coronary artery bypass graft surgery.
WardropDKeelingD. The story of the discovery of heparin and warfarin. Br J Haematol2009; 141: 757–765.
2.
DespotisGJJoistJHHogueCWJr. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg1995; 110: 46–54.
3.
LewandrowskiELVan CottEMGregoryK. Clinical evaluation of the i-STAT kaolin activated clotting time test in different clinical settings in a large academic urban medical center. Comparison with the Medtronic ACT Plus. Amer J Clin Path2011; 135: 741–748.
4.
BrayBLaneDAFreyssinetJM. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J1989; 262: 225–232.
5.
DespotisGJGraveleeGFilosF. Anticoagulation monitoring during cardiac surgery. Anethesiology1999; 91: 1122–1151.
6.
GuytonACHallJE. Textbook of Medical Physiology. (p469) 9th ed. Philadelphia, PA, USA: W.B. Saunders Company 1996 .
TollefsenDM. Insight into the mechanism of action of heparin cofactor II. Throm Haemostasis1995; 74: 1209–1214.
9.
RosenbergRDDamusPS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem1973; 248: 6490–6505.
10.
JohnLCReesGMKovacIB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg1993; 105: 816–822.
11.
KuriSFValeriCRLoscalzoJ. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg1995; 60: 1008–1014.
12.
HanJHiebertLM. Alteration in endothelial proteoglycan and heparanse gene expression by high glucose, insulin and heparin. Vas Pharacol2013; 59: 112–118.
13.
GravleeGPDavisRFStammersAHUngerleiderRM. Cardiopulmonary Bypass: Principles and Practice. Lipincot Williams & Wilkins, 2007; p111–115.
14.
AvidanMSLeveyJHVan AkenH. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg2005; 130: 107–113.
15.
WarkentinTEGreinacherAKosterA. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008; 133: 340S.
16.
FinleyAGreenbergC. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg2013; 116: 1210–1222.
17.
AvidanMSLevyJHScholzJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology2005; 102: 276–284.
KnapikPCieślaDPrzybylskiRKnapikT. The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery. Med Sci Monit2012; 18: CR105–111.
20.
ChanTHwangNCLimCHA. Statistical analysis of factors predisposing patients to heparin resistance. Perfusion2006; 21: 99–103.
21.
GormanRCZiatsNRaoAK. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg1996; 111: 1–11.
22.
MartindaleSJShayevitzJRD’ ErricoC. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric surgery. J Cardiothorac Vasc Anesth1996; 10: 458–463.
23.
RaymondPDMarshNA. Alterations to hemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity. Blood Coagul Fibrinolysis2001; 12: 601–618.
24.
BullBSHuseWMBrauerFSKorpmanRA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg1975; 69: 685–689.
25.
RaymondPDRayMJCallenSN. Heparin monitoring during cardiac surgery. Part I: Validation of whole-blood heparin concentration and activated clotting time. Perfusion2003; 18: 269–276.
26.
HashimotoKSasakiTHachyaT. Real time measurement of heparin concentration during cardiopulmonary bypass. J Cardiovasc Surg1999; 40: 645–651.
27.
HardyJFBélisleSRobitailleDPerraultJRoyMGagnonL. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg1996; 112: 154–161.
28.
WahrJAYunJHYanngVCLeeLMMeyerhoffME. A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor. J Cardiothorac Vas Anesth1996; 10: 447–450.
29.
GruenwaldCde SouzaVChanAKAndrewM. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Perfusion2000; 15: 203–209.
WarkentinTE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North A2010; 24: 755–775.
32.
GrubbKJSalehiPChedrawyEG. Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Recent Pat Cardiovasc Drug Discov2010; 5: 20–24.
33.
NikolaidisNVelissarisTOhriSK. Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case. Tex Heart Inst J2007; 34: 115–118.
34.
ToschiVLettinoMGalloRBadimonJJChesebroJH. Biochemistry and biology of hirudin. Coron Artery Dis1996; 7: 420–428.
35.
MaraganoreJMAdelmanBA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis1996; 7: 438–448.
36.
KosterABuzSKrabatschTYeterRHetzerR. Bivalirudin anticoagulation during cardiac surgery: a single-center experience in 141 patients. Perfusion2009; 24: 7–11.
37.
WeitzJI. A novel approach to thrombin inhibition. Thromb Res2003; 109: S17–22.
38.
GladwellTD. Bivalirudin: a direct thrombin inhibitor. Clin Ther2002; 24: 38–58.
39.
BatesSMWeitzJI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol1998; 82: 12–18.
40.
LidónRMThérouxPJuneauMAdelmanBMaraganoreJ. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation1993; 88: 1495–1501.
41.
EichlerPLubenowNStrobelUGreinacherA. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood2004; 103: 613–616.
ClaytonSBAcsellJRCrumbleyAJ3rdUberWE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg2004; 78: 2167–2169.
44.
KosterAChewDGrundelM. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypassAnesth Analg2003; 96: 383–386.
45.
BatesER. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther2004; 2: 153–156.
46.
KosterARosendahlUvon HodenbergEEnnkerJ. Management of protamine allergy with bivalirudin during coronary artery revascularization. Ann Thorac Surg2010; 90: 276–277.
47.
PappalardoFFrancoACrescenziGPoliAZangrilloAKosterA. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Perfusion2007; 22: 67–69.
48.
Bivalirudin [package insert].Bedford, Ohio, USA: Ben Venue Laboratories; 2005.
49.
Ecarin Clotting Time Product Literature. Cardiovascular Diagnostics Inc., Raleigh, North Carolina, USA
50.
WigginsSSpinlerSWittkowskyAK. Bivalirudin: a direct thrombin inhibitor for percutaneous coronary angioplasty. Phamacotherapy2002; 22: 1007–1018.
51.
NowakG. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb2003Jul-2004Aug; 33: 173–183.
52.
FabrizioMC. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol2001; 33: 117–125.
53.
WarkentinTEKeltonJG. A 14-year study of heparin-induced thrombocytopenia. Am J Med1996; 101: 502–507.
KosterABuzSKrabatschT. Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system. J Card Surg2008; 23: 321–323.
58.
PreissDUAbdullahDEberspächerBWilhelmK. Safety of virus inactivated antithrombin III concentrate antithrombin III immuno (AT III). Thromb Res1992; 65: 677–686.
59.
WilliamsMRD’AmbraABBeckJR. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg2000; 70: 873–877.
60.
SchwartzRSBauerKARosenbergRDKavanaughEJDaviesDCBogdanoffDA. The Antithrombin III Study Group. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med1989; 87: 53S-60S.
61.
LemmerJHDespotisGE. Antithrombin III concentrates to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg2002; 123: 213–217.
62.
BucurSZLevyJHDespotisGJSpiessBDHillyerCD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion1998; 38: 481–498.
BeattieGWJeffreyRR. Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery?Interactive Card Vascu and Thorac Surg2014; 18: 117–120.
65.
AvidanMSLeyJHScholzJ. A phase III, double-blind, placebo controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology2005; 102: 276–284.
66.
SpiessBD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg2008; 85: 2153–2160.
67.
AnandSXViles-GonzalezJFMahboobiSKHeerdtPM. Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anaesth2011; 58: 296–311.
68.
RanaRFernandez-PerezERKhanSA. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion2006; 46: 1478–1483.
69.
HolnessLKnippenMALachenbruchPA. Fatalities caused by TRALI. Transf Med Rev2004; 18: 184–188.
70.
BuxJ. Transfusion-related acute lung injury (TRALI); a serious adverse event of blood transfusionVox Sang2005; 89: 1–10.
71.
Van NormanGAGernsheimerTChandlerWL. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin III administration for acquired antithrombin II deficiency. J Cardiothorac Vas Anesth1997; 11: 760–763.
72.
TonerRWPizziLLeasB. Cost to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy2011; 9: 29–37.
73.
BoothNA. Fibrinolysis and thrombosis. Baillieres Best Prac Res Clin Haematol1999; 12: 423–433.
74.
Niimi Y, Ichinose F, IshiguroY, et al.The effects of heparin coating of oxygenator fibers on platelet adhesion and protein adsorption. Anesth Analg1999; 89: 573–579.
75.
KeurenJFWieldersSJWillems. Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost2002; 87: 742–747.
76.
NishidaHAomiSTomizawaY. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass. Artif Organs1999; 23: 547–551.
77.
BlombäckMKronlundPAbergB. Pathologic fibrin formation and cold-induced clotting of membrane oxygenators during cardiopulmonary bypass. Cardiothorac Vasc Anesth1995; 9: 34–43.
78.
SchaadtJ. Oxygenator thrombosis: an international phenomenon. Perfusion1999; 14: 425–435.
79.
SniecinskiRMChandlerWL. Activation of the hemostatic system during cardiopulmonary bypassAnesth Analg2011; 113: 1319–1333.
80.
GallimoreMJJonesDWWinterM. Changes in high molecular weight kininogen levels during and after cardiopulmonary bypass surgery measured using chromogenic peptide substrate assay. Blood Coagul Fibrinolysis2002; 13: 561–568.
81.
DhirA. Antifibrinolytics in cardiac surgery. Ann Card Anaeth2013; 16: 117–125.
82.
PretoriusMSchollFGMcFarlaneJA. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther2005; 78: 477–485.
83.
FuhrerGGallimoreMJHellerW. Aprotinin in cardiopulmonary bypass: effect on the Hageman factor (FXII)-kallikrein system and blood loss. Blood Coagul Fibrinolysis1992; 3: 99–104.
84.
ChandlerWLVelanT. Secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 during cardiopulmonary bypass. Throm Res2003; 112: 185–192.
85.
ChandlerWLValenT. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coag Fibrinol2004; 15: 583–591.
86.
ChandlerWLFitchJCWallMH. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost1995; 74: 1293–1297.
87.
ValenGErikssonERisbergBVaageJ. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg1994; 8: 324–330.
88.
TanakaKTakaoMYadaIYuasaHKusagawaMDeguchiK. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open-heart surgery. J Cardiothorac Anesth1989; 3: 181–188.
89.
DykeCMSmediraNGKosterA. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg2006; 131: 533–539.
90.
KosterASpiessBJurmannM. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the “EVOLUTION OFF” trial. Anesth Analg2006; 103: 540–544.
91.
KosterADykeCMAldeaG. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg2007; 83: 572–577.
92.
KosterABuzSKrabatschTYeterRHetzerR. Bivalirudin anticoagulation during cardiac surgery: a single-center experience in 141 patients. Perfusion2009; 24: 7–11.
93.
VuylstekeAMillsRJCrosbieAEBurnsTILatimerRD. Increased pre-operative platelet counts are a possible predictor for reduced sensitivity to heparin. Br J Anaesth2000; 85: 896–898.
94.
RanucciMIsgròGCazzanigaASoroGMenicantiLFrigiolaA. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion1999; 14: 437–442.
